In recent years, the Von Willebrand disease (factor VIII deficiency) market is anticipated to grow rapidly during the forecast period. The rise in patient support programmes is a primary driver of industry expansion. The PAN Foundation launched a new patient aid programme for persons with von Willebrand disease in July 2021. Patients who qualify for the programme will get USD 10,200 per year in financial support to cover deductibles, co-pays, and coinsurance costs related with their von Willebrand disease therapy.
Frequently Asked Questions
The market is segmented based on Global Von Willebrand Disease (Factor VIII Deficiency) Market Segmentation, By Type (Type 1 von Willebrand Disease, Type 2 von Willebrand Disease, Type 3 von Willebrand Disease), Drugs (Antihemophilic Factor/Von Willebrand Factor Complex, Von Willebrand Factor/Coagulation Factor VIII Complex, Von Willebrand factor (Recombinant), Desmopressin Acetate and Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Von Willebrand Disease Market size was valued at USD 584.62 USD Million in 2024.
The Global Von Willebrand Disease Market is projected to grow at a CAGR of 5.99% during the forecast period of 2025 to 2032.
The major players operating in the market include Novo Nordisk, Sun Pharmaceutical Industries, Zydus Cadila, Baxter, Glenmark Pharmaceuticals Limited, Bausch Health Companies, Bayer, Mylan, Teva Pharmaceutical Industries, Sanofi, Pfizer, GlaxoSmithKline, Novartis, F. Hoffmann La Roche, Merck & Co., Allergan, Cipla, Abbott, AbbVie, Merck KGaA, Amneal Pharmaceuticals, Boehringer Ingelheim International GmbH.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
